Biofrontera Inc.

NasdaqCM:BFRI Stock Report

Market Cap: US$12.8m

Biofrontera Management

Management criteria checks 3/4

Biofrontera's CEO is Hermann Luebbert, appointed in May 2023, has a tenure of 3.08 years. total yearly compensation is $873.23K, comprised of 56.1% salary and 43.9% bonuses, including company stock and options. directly owns 2.42% of the company’s shares, worth $309.41K. The average tenure of the management team and the board of directors is 3.3 years and 4.6 years respectively.

Key information

Hermann Luebbert

Chief executive officer

US$873.2k

Total compensation

CEO salary percentage56.08%
CEO tenure3.1yrs
CEO ownership2.4%
Management average tenure3.3yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

Analysis Article • Jan 23

There's No Escaping Biofrontera Inc.'s (NASDAQ:BFRI) Muted Revenues Despite A 42% Share Price Rise

Those holding Biofrontera Inc. ( NASDAQ:BFRI ) shares would be relieved that the share price has rebounded 42% in the...
Analysis Article • Oct 04

Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Its Share Price

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Biofrontera Inc. ( NASDAQ:BFRI ) is definitely a...
User avatar
New Narrative • May 05

FDA Approval And Product Expansion Will Unlock New Markets

FDA approval for expanded Ameluz use and restructuring agreements enhance margins, supporting future revenue growth through increased average sales size and reduced costs.
Analysis Article • Feb 27

Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues

Biofrontera Inc.'s ( NASDAQ:BFRI ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right...
Analysis Article • Sep 28

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Biofrontera Inc. ( NASDAQ:BFRI ) shares have continued their recent momentum with a 25% gain in the last month alone...
Analysis Article • Aug 09

Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Those holding Biofrontera Inc. ( NASDAQ:BFRI ) shares would be relieved that the share price has rebounded 40% in the...
Analysis Article • May 24

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

Biofrontera Inc. ( NASDAQ:BFRI ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...
Analysis Article • Dec 30

Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

Unfortunately for some shareholders, the Biofrontera Inc. ( NASDAQ:BFRI ) share price has dived 28% in the last thirty...

CEO Compensation Analysis

How has Hermann Luebbert's remuneration changed compared to Biofrontera's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$873kUS$490k

-US$11m

Sep 30 2025n/an/a

-US$18m

Jun 30 2025n/an/a

-US$17m

Mar 31 2025n/an/a

-US$12m

Dec 31 2024US$1mUS$482k

-US$18m

Sep 30 2024n/an/a

-US$13m

Jun 30 2024n/an/a

-US$14m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$733kUS$471k

-US$20m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$475k

-US$640k

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$26m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$1mUS$18k

-US$38m

Compensation vs Market: Hermann's total compensation ($USD873.23K) is above average for companies of similar size in the US market ($USD647.77K).

Compensation vs Earnings: Hermann's compensation has been consistent with company performance over the past year.

CEO

Hermann Luebbert (70 yo)

3.1yrs
Tenure
US$873,232
Compensation

Dr. Prof. Hermann Luebbert, Ph.D. is a Co-Founder of Biofrontera AG and served as its Chief Executive Officer since 1997 until December 13, 2021 and served as its Chairman of Management Board since 2000 un...

Leadership Team

NamePositionTenureCompensationOwnership
Hermann Luebbert
CEO, President & Chairman3.1yrsUS$873.23k2.42%
$ 309.4k
Eugene Leffler
Chief Financial Officer3.7yrsUS$554.21k1.46%
$ 186.6k
George Jones
Chief Commercial Officerless than a yearUS$335.68kno data
Erica Gates
VP of Finance & Principal Accounting Officerno datano datano data
Jon Lyons
Vice President of Scientific & Medical Affairs3.4yrsno datano data
Daniel Hakansson
Senior Corporate Counsel7.4yrsno datano data
Samantha Widdicombe
Senior Vice President of Sales & Strategic Accounts1.4yrsno datano data
3.3yrs
Average Tenure
53yo
Average Age

Experienced Management: BFRI's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hermann Luebbert
CEO, President & Chairman11.3yrsUS$873.23k2.42%
$ 309.4k
John Borer
Independent Director4.6yrsUS$87.25kno data
Heikki Lanckriet
Director2.9yrsUS$60.25kno data
Kevin Weber
Independent Director4.3yrsUS$88.25kno data
Beth Hoffman
Independent Director4.6yrsUS$84.25kno data
4.6yrs
Average Tenure
68yo
Average Age

Experienced Board: BFRI's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/25 21:57
End of Day Share Price 2026/06/25 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biofrontera Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Jonathan AschoffRoth Capital Partners